tradingkey.logo
tradingkey.logo
Search

Neuropace Inc

NPCE
Add to Watchlist
15.360USD
-0.430-2.72%
Close 05/15, 16:00ETQuotes delayed by 15 min
511.19MMarket Cap
LossP/E TTM

Neuropace Inc

15.360
-0.430-2.72%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.72%

5 Days

-16.29%

1 Month

-0.78%

6 Months

+18.70%

Year to Date

-0.52%

1 Year

-12.18%

TradingKey Stock Score of Neuropace Inc

Currency: USD Updated: 2026-05-15

Key Insights

Neuropace Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 58 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.86.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Neuropace Inc's Score

Industry at a Glance

Industry Ranking
58 / 206
Overall Ranking
148 / 4482
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Neuropace Inc Highlights

StrengthsRisks
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 52.83% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 99.99M.
Undervalued
The company’s latest PE is -23.81, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 33.54M shares, decreasing 11.02% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 2.81K shares of this stock.

Analyst Rating

Based on 8 analysts
Buy
Current Rating
19.857
Target Price
+25.76%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Neuropace Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Neuropace Inc Info

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Ticker SymbolNPCE
CompanyNeuropace Inc
CEOBecker (Joel D)
Websitehttps://www.neuropace.com/
KeyAI